Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia

Leukemia. 2009 Jan;23(1):190-4. doi: 10.1038/leu.2008.160. Epub 2008 Jul 3.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Dasatinib
  • Female
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Hematopoietic Stem Cell Transplantation / methods*
  • Hematopoietic Stem Cell Transplantation / mortality
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Male
  • Middle Aged
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrimidines / administration & dosage*
  • Retrospective Studies
  • Survival Analysis
  • Thiazoles / administration & dosage*
  • Treatment Outcome
  • Young Adult

Substances

  • Protein Kinase Inhibitors
  • Pyrimidines
  • Thiazoles
  • nilotinib
  • Dasatinib